Inventor · disambiguated record
Lori C. Morton
Also filed as: MORTON LORI · MORTON LORI C
16 granted patents·17 pending applications·41 citations·filing 2013–2025
90Inventor score
Files withREGENERON PHARMA33
Top patents by PatentIndex Score
33 records- 0194US9718881B2Anti-Activin A antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Aug 1, 2017·21 cites·44 claims
- 0293US11820826B2Anti-NPR1 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Nov 21, 2023·2 cites·14 claims
- 0388US11306148B2Anti-NPR1 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Apr 19, 2022·3 cites·11 claims
- 0487US10526403B2Anti-activin A antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Jan 7, 2020·4 cites·43 claims
- 0585US10377817B2Human antibodies to GREM1REGENERON PHARMA·Filed 2014·Granted Aug 13, 2019·7 cites·13 claims
- 0682US2024309103A1Anti-npr1 antibodies and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0781US2024059780A1Anti-npr1 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0880US11737435B2Non-human animals comprising a humanized coagulation factor 12 locusREGENERON PHARMA·Filed 2020·Granted Aug 29, 2023·1 cites·17 claims
- 0980US11622547B2Genetically modified mouse that expresses human albuminREGENERON PHARMA·Filed 2020·Granted Apr 11, 2023·1 cites·12 claims
- 1080US2023312699A1Anti-activin a antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1177US12201096B2Non-human animals comprising a humanized coagulation factor 12 locusREGENERON PHARMA·Filed 2023·Granted Jan 21, 2025·0 cites·16 claims
- 1274US12317874B2Method of using a genetically modified mouse that expresses human albuminREGENERON PHARMA·Filed 2023·Granted Jun 3, 2025·0 cites·30 claims
- 1373US10765762B2Humanized model of kidney and liver disordersREGENERON PHARMA·Filed 2018·Granted Sep 8, 2020·2 cites·16 claims
- 1470US2023192831A1Human Antibodies to GREM1REGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1569US12325752B2Immunoglobulin proteins that bind to NPR1 agonistsREGENERON PHARMA·Filed 2021·Granted Jun 10, 2025·0 cites·44 claims
- 1669US2021163583A1Anti-activin a antibodies and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1766US2024190996A1Factor xi catalytic domain-binding antibodies and methods of use thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1865US2025333524A1Immunoglobulin proteins that bind to npr1 agonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1964US11634480B2Human antibodies to GREM1REGENERON PHARMA·Filed 2019·Granted Apr 25, 2023·0 cites·12 claims
- 2064US2024158795A1Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2162US2024425574A1Anti-pdgf-b antibodies and pharmaceutical composition thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2261US2023193271A1Treatment Of Kidney Diseases With Angiopoietin Like 3 (ANGPTL3) InhibitorsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2359US12304969B2Factor XI A2 domain-binding antibodies and methods of use thereofREGENERON PHARMA·Filed 2022·Granted May 20, 2025·0 cites·20 claims
- 2459US2025277021A1Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A AntagonistsREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2558US12030935B2Anti-PDGF-B antibodies and pharmaceutical composition thereofREGENERON PHARMA·Filed 2022·Granted Jul 9, 2024·0 cites·9 claims
- 2657US2024415980A1Crispr/cas-related methods and compositions for knocking out c5REGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2755US2022056119A1Methods for Preventing and Treating Cardiac Dysfunction and COVID-19 with Activin A AntagonistsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2852US2022053741A1Complement Factor H Gene Knockout Rat as a Model of C3 GlomerulopathyREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 2944US9751932B2Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereofREGENERON PHARMA·Filed 2013·Granted Sep 5, 2017·0 cites·20 claims
- 3043US2018008672A1Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertensionREGENERON PHARMA·Filed 2017·Application pending·0 cites
- 3142US2019002555A1Antigen-binding proteins to marinobufageninREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 3240US12068729B2Anti-factor XII/XIIa antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Aug 20, 2024·0 cites·31 claims
- 3338US2018057580A1Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertensionREGENERON PHARMA·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lori C. Morton files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →